Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

S. A. Watson, T. M. Morris, S. L. Parsons, R. J. Steele, P. D. Brown

    Research output: Contribution to journalArticle

    52 Citations (Scopus)

    Abstract

    The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P
    Original languageEnglish
    Pages (from-to)1354-1358
    Number of pages5
    JournalBritish Journal of Cancer
    Volume74
    Issue number9
    DOIs
    Publication statusPublished - 1996

    Keywords

    • Animals
    • Antineoplastic Agents
    • Ascitic Fluid
    • Colorectal Neoplasms
    • Drug Screening Assays, Antitumor
    • Female
    • Humans
    • Metalloendopeptidases
    • Mice
    • Mice, SCID
    • Phenylalanine
    • Thiophenes
    • Tumor Cells, Cultured

    Fingerprint Dive into the research topics of 'Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model'. Together they form a unique fingerprint.

  • Cite this